scholarly journals Platelet-to-hemoglobin ratio as a valuable predictor of long-term all-cause mortality in coronary artery disease patients with congestive heart failure

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Kunming Bao ◽  
Haozhang Huang ◽  
Guoyong Huang ◽  
Junjie Wang ◽  
Ying Liao ◽  
...  

Abstract Background The platelet-to-hemoglobin ratio (PHR) has emerged as a prognostic biomarker in coronary artery disease (CAD) patients after PCI but not clear in CAD complicated with congestive heart failure (CHF). Hence, we aimed to assess the association between PHR and long-term all-cause mortality among CAD patients with CHF. Methods Based on the registry at Guangdong Provincial People’s Hospital in China, we analyzed data of 2599 hospitalized patients who underwent coronary angiography (CAG) and were diagnosed with CAD complicated by CHF from January 2007 to December 2018. Low PHR was defined as ˂ 1.69 (group 1) and high PHR as ≥ 1.69 (group 2). Prognosis analysis was performed using Kaplan–Meier method. To assess the association between PHR and long-term all-cause mortality, a Cox-regression model was fitted. Results During a median follow-up of 5.2 (3.1–7.8) years, a total of 985 (37.9%) patients died. On the Kaplan–Meier analysis, patients in high PHR group had a worse prognosis than those in low PHR group (log-rank, p = 0.0011). After adjustment for confounders, high PHR was correlated with an increased risk of long-term all-cause mortality in CAD patients complicated with CHF. (adjusted hazard ratio [aHR], 1.31; 95% confidence interval [CI], 1.13–1.52, p < 0.0001). Conclusion Elevated PHR is correlated with an increased risk of long-term all-cause mortality in CAD patients with CHF. These results indicate that PHR may be a useful prognostic biomarker for this population. Meanwhile, it is necessary to take effective preventive measures to regulate both hemoglobin levels and platelet counts in this population.

2021 ◽  
Author(s):  
Kunming Bao ◽  
Haozhang Huang ◽  
Guoyong Huang ◽  
Junjie Wang ◽  
Ying Liao ◽  
...  

Abstract Background The platelet-to-hemoglobin ratio (PHR) has emerged as a prognostic biomarker in coronary artery disease (CAD) patients after PCI but not clear in CAD complicated with congestive heart failure (CHF). Hence, we aimed to assess the association between PHR and long-term all-cause mortality among CAD patients with CHF. Methods Based on the registry at Guangdong Provincial People’s Hospital in China, we analyzed data of 2,599 hospitalized patients who underwent coronary angiography (CAG) and were diagnosed with CAD complicated by CHF from January 2007 to December 2018. Low PHR was defined as˂1.69 (group 1) and high PHR as ≥ 1.69 (group 2). Prognosis analysis was performed using Kaplan-Meier methods. To assess the association between PHR and long-term all-cause mortality, a Cox-regression model was fitted. Results During a median follow-up of 5.2 (3.1–7.8) years, a total of 985 (37.9%) patients died. On the Kaplan-Meier analysis, patients in high PHR group had a worse prognosis than low PHR group (log-rank, p = 0.0011). After adjustment for confounders, high PHR was correlated with an increased risk of long-term all-cause mortality in CAD patients complicated with CHF. (adjusted hazard ratio [aHR], 1.21; 95% confidence interval [CI], 1.03–1.41, p = 0.02). Conclusion Elevated PHR is correlated with an increased risk of long-term all-cause mortality in CAD patients with CHF. These results indicate that PHR may be a useful prognostic biomarker for this population. Meanwhile, it is necessary to take effective preventive measures to regulate both hemoglobin levels and platelet counts in this population.


2021 ◽  
Vol 8 ◽  
Author(s):  
Haozhang Huang ◽  
Jin Liu ◽  
Yan Liang ◽  
Kunming Bao ◽  
Linfang Qiao ◽  
...  

Background: Hypochloremia is an independent predictor for mortality in patients with coronary artery disease (CAD) but whether the same correlation exists in CAD patients with congestive heart failure (CHF) is unclear.Methods: This is an analysis of data stored in the databases of the CIN-I [a registry of Cardiorenal Improvement (NCT04407936) in China from January 2007 to December 2018] and Medical Information Mart for Intensive Care (MIMIC)-III. CAD patients with CHF were included. The outcome measures were 90-day all-cause mortality (ACM) and long-term ACM.Results: Data from 8,243 CAD patients with CHF were analyzed. We found that 10.2% of the study population had hypochloremia (Cl− &lt;98 mmol/L) in CIN-I (n = 4,762) and 20.1% had hypochloremia in MIMIC-III (n = 3,481). Patients suffering from hypochloremia were, in general, older and had a higher prevalence of comorbidities. After adjustment for confounders, hypochloremia remained a significant predictor of short-term mortality risk [90-day ACM: adjusted hazard ratio (aHR), 1.69; 95% CI, 1.27–2.25; P &lt; 0.001 in CIN-I, and 1.36 (1.17–1.59); P &lt; 0.001 in MIMIC-III]. Hypochloremia was also associated with long-term mortality [aHR, 1.26; 95% CI, 1.06–1.50; P = 0.009 in CIN-I, and 1.48 (1.32–1.66); P &lt; 0.001 in MIMIC-III]. Prespecified subgroup analyses revealed an association of hypochloremia with long-term ACM to be attenuated slightly in the women of the two databases (P interaction &lt; 0.05).Conclusions: Hypochloremia is independently associated with higher short-term and long-term ACM. Further studies are needed to determine if early preventive measurements and active intervention of hypochloremia can reduce the mortality risk of CAD patients with CHF.


2020 ◽  
Author(s):  
Man Li ◽  
Lei Duan ◽  
Yulun Cai ◽  
Benchuan Hao ◽  
Jianqiao Chen ◽  
...  

Abstract Background: Suppression of tumorigenesis-2 is implicated in the myocardial overload and it was long been recognized as an inflammation marker related to heart failure and acute coronary syndromes, but the data on prognostic value of suppression of tumorigenesis-2 on patients with coronary artery disease remains limited. The study ought to investigate the prognostic value of suppression of tumorigenesis-2 in patients with established coronary artery disease.Methods: In this prospective cohort study, a total of 3641 consecutive patients were included. The primary end point was major adverse cardiovascular events. Kaplan-Meier survival estimates indicated that the patients with higher levels of ST2 (ST2> 19 ng/ml) had a significantly increased risk of MACEs (log-rank p<0.001) and all-cause death (log-rank p<0.001). The secondary end point was all-cause death. The association between suppression of tumorigenesis-2 and outcomes was investigated using multivariable COX regression.Results: During a median follow up of 6.4 years, there were 775 patients had the occurrence of major adverse cardiovascular events and 275 patients died. Kaplan-Meier survival estimates indicated that the patients with higher levels of ST2 (ST2> 19 ng/ml) had a significantly increased risk of MACEs (log-rank p<0.001) and all-cause death (log-rank p<0.001). Multiple COX regression models showed that higher level of suppression of tumorigenesis-2 was an independent predictor in developing major adverse cardiovascular events (HR=1.36, 95% CI 1.17-1.56, p<0.001) and all-cause death (HR=2.01, 95%CI 1.56-2.59, p<0.001). The addition of suppression of tumorigenesis-2 to established risk factors significantly improved risk prediction of the composite outcome of major adverse cardiovascular events and all-cause death (c-statistic, net reclassification index, and integrated discrimination improvement, all p<0.05).Conclusions: Higher level of suppression of tumorigenesis-2 is significantly associated with long-term all-cause death and major adverse cardiovascular events. Suppression of tumorigenesis-2 may provide incremental prognostic value beyond traditional risk factors.


Cardiology ◽  
2007 ◽  
Vol 107 (3) ◽  
pp. 178-184 ◽  
Author(s):  
Heidi T. May ◽  
Rami Alharethi ◽  
Jeffrey L. Anderson ◽  
Joseph B. Muhlestein ◽  
Sandra P. Reyna ◽  
...  

1993 ◽  
Vol 72 (15) ◽  
pp. 1156-1162 ◽  
Author(s):  
Yaver Bashir ◽  
James F. Sneddon ◽  
H.Anne Staunton ◽  
Guy A. Haywood ◽  
Iain A. Simpson ◽  
...  

2021 ◽  
Author(s):  
Huanqiang Li ◽  
Bo Wang ◽  
Ziling Mai ◽  
Sijia Yu ◽  
Ziyou Zhou ◽  
...  

Abstract Background Apolipoprotein B (ApoB) and low-density lipoprotein cholesterol (LDL-C) was identified as the target for blood lipid management among coronary artery disease (CAD) patients. Previous studies reported an inverse correlation between baseline LDL-C concentration and clinical outcomes. However, the association between baseline ApoB concentration and long-term prognosis is unknown. Methods 36,486 CAD patients admitted to Guangdong Provincial People's Hospital in China were enrolled in this study and patients were categorized into two groups: high concentration of ApoB (≥65 mg/dL) group and low concentration of ApoB (< 65 mg/dL) group. The association between ApoB levels and long-term all-cause mortality was evaluated by the Kaplan-Meier method and Cox regression analyses. Results The overall mortality was 12.49% (n = 4,554) over a median follow-up period of 5.01 years. According to Kaplan–Meier analysis, patients with low baseline ApoB levels were paradoxically more likely to get a worse prognosis. Multivariate Cox regression analyses were performed to adjust for confounding factors such as age, gender, and comorbidity, and there was no obvious difference in long-term all-cause mortality among ApoB patients (aHR: 1.07, 95% CI: 0.99-1.16). When CONUT and total bilirubin were adjusted, the risk of long-term all-cause mortality would reduce in the low-ApoB (< 65mg/dl) group (aHR: 0.86, 95% CI: 0.78-0.96). In the fully covariable-adjusted model, patients in the ApoB < 65mg/d group had a 10.00% lower risk of long-term all-cause death when comparing to patients with ApoB≥65mg/dL (aHR: 0.90; 95% CI:0.81-0.99). Conclusion This study found a paradoxical association between baseline ApoB concentration and long-term all-cause mortality. Malnutrition and bilirubin mainly mediate the ApoB paradox.


Sign in / Sign up

Export Citation Format

Share Document